Ivantis Inc. has raised $25 million in financing to fund future U.S. commercialization of its Hydrus™ Microstent device designed to lower eye pressure for glaucoma patients, upon anticipated 2018 approval by the U.S. FDA.
The Hydrus Microstent is reportedly a next-generation Minimally Invasive Glaucoma Surgery (MIGS) device placed through a microsurgical procedure. About the size of an eyelash, the device is designed to reduce eye pressure by reestablishing the patient's natural outflow pathway.
While the current U.S. pivotal trial is evaluating the Hydrus Microstent in glaucoma patients who are undergoing cataract surgery, the device is reportedly being used both in cataract surgery and in standalone glaucoma surgery internationally.
Photo courtesy Ivantis
Click here to read the full press release.